These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34955876)

  • 1. Overactive Bladder Symptoms Within Nervous System: A Focus on Etiology.
    Qin C; Wang Y; Gao Y
    Front Physiol; 2021; 12():747144. PubMed ID: 34955876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
    Peyronnet B; Mironska E; Chapple C; Cardozo L; Oelke M; Dmochowski R; Amarenco G; Gamé X; Kirby R; Van Der Aa F; Cornu JN
    Eur Urol; 2019 Jun; 75(6):988-1000. PubMed ID: 30922690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
    Chen SF; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiology and etiology of overactive bladder].
    Hampel C; Gillitzer R; Pahernik S; Hohenfellner M; Thüroff JW
    Urologe A; 2003 Jun; 42(6):776-86. PubMed ID: 12851768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
    Nik-Ahd F; Lenore Ackerman A; Anger J
    Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder?
    Giarenis I; Mastoroudes H; Srikrishna S; Robinson D; Cardozo L
    BJU Int; 2013 Aug; 112(4):501-7. PubMed ID: 23452071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overactive bladder: urodynamic characteristics of detrusor overactivity due to the etiology of low urinary tract dysfun- ction].
    Philippova ES; Bazhenov IV; Ziryanov AV; Zhuravlev VN
    Urologiia; 2021 Jun; (3):39-44. PubMed ID: 34251099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic detrusor overactivity in patients with overactive bladder symptoms.
    Al-Ghazo MA; Ghalayini IF; Al-Azab R; Hani OB; Matani YS; Haddad Y
    Int Neurourol J; 2011 Mar; 15(1):48-54. PubMed ID: 21468287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactive bladder (OAB): A symptom in search of a disease - Its relationship to specific lower urinary tract symptoms and conditions.
    Van Batavia JP; Combs AJ; Fast AM; Glassberg KI
    J Pediatr Urol; 2017 Jun; 13(3):277.e1-277.e4. PubMed ID: 28527720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Male non-neurogenic overactive bladder].
    Phé V; Gamé X
    Prog Urol; 2020 Nov; 30(14):880-886. PubMed ID: 33220816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome.
    Kuo HC; Liu HT; Guan Z; Tyagi P; Chancellor MB
    Low Urin Tract Symptoms; 2011 Apr; 3(1):2-9. PubMed ID: 26676344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
    Liu HT; Chen CY; Kuo HC
    J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
    Dokmeci F; Cetinkaya SE; Seval MM; Dai O
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
    Yokoyama T; Kumon H; Nagai A
    Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome.
    Kuo HC
    Low Urin Tract Symptoms; 2012 Mar; 4 Suppl 1():32-41. PubMed ID: 26676698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurogenic Causes of Detrusor Underactivity.
    Kadow BT; Tyagi P; Chermansky CJ
    Curr Bladder Dysfunct Rep; 2015 Dec; 10(4):325-331. PubMed ID: 26715948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity.
    Abrams P
    Urology; 2003 Nov; 62(5 Suppl 2):28-37; discussion 40-2. PubMed ID: 14662404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.